Skip to main content
SpringerLink
Log in

Hypotheses Regarding Ayahuasca’s Potential Mechanisms of Action in the Treatment of Addiction

  • Chapter
The Therapeutic Use of Ayahuasca

Abstract

Drug addiction is an epidemic problem affecting millions worldwide with high rates of morbidity and mortality. Although the number of pharmacological options available to treat addiction has increased, these treatments demonstrate only modest efficacy. New treatments with improved efficacy rates and favorable side effect profiles are needed. Ayahuasca is a medicine that is increasingly being utilized to treat addictions. However, despite its growing popularity, the mechanisms underlying ayahuasca’s effectiveness as a treatment for addictions remain unknown. We propose biochemical, physiological, psychological, and transcendent hypotheses to explain how ayahuasca treats addictions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adinoff, B. (2004). Neurobiologic processes in drug reward and addiction. Harvard Review of Psychiatry, 12(6), 305–320.

    PubMed  PubMed Central  Google Scholar 

  • Alex, K. D., & Pehek, E. A. (2007). Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacology & Therapeutics, 113(2), 296–320.

    CAS  Google Scholar 

  • Anton, R. F., O’Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., et al. (2006). Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. JAMA, 295(17), 2003–2017. doi:10.1001/jama.295.17.2003.

  • Berke, J. D., Paletzki, R. F., Aronson, G. J., Hyman, S. E., & Gerfen, C. R. (1998). A complex program of striatal gene expression induced by dopaminergic stimulation. Journal of Neuroscience, 18, 5301–5310.

    CAS  PubMed  Google Scholar 

  • Berridge, K. C. (2007). The debate over dopamine’s role in reward: The case for incentive salience. Psychopharmacology (Berl), 191, 391–431.

    CAS  Google Scholar 

  • Blum, K., Sheridan, P. J., Wood, R. C., Braverman, E. R., Chen, T. J., Cull, J. G., et al. (1996). The D2 dopamine receptor gene as a determinant of Reward Deficiency Syndrome. Journal of the Royal Society of Medicine, 89(7), 396–400.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Blum, K., Werner, T., Carnes, S., Carnes, P., Bowirrat, A., Giordano, J., et al. (2012). Sex, drugs, and rock ‘n’ roll: Hypothesizing common mesolimbic activation as a function of reward gene polymorphisms. Journal of Psychoactive Drugs, 44(1), 38–55. doi:10.1080/02791072.2012.662112.

  • Bramham, C. R., & Messaoudi, E. (2005). BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Progress in Neurobiology, 76(2), 99–125.

    CAS  PubMed  Google Scholar 

  • Brierley, D. I., & Davidson, C. (2012). Harmine augments electrically evoked dopamine efflux in the nucleus accumbens shell. Journal of Psychopharmacology, 27(3), 98–108. doi:10.1177/0269881112463125.

    Article  CAS  PubMed  Google Scholar 

  • Camí, J., & Farre, M. (2003). Drug addiction. New England Journal of Medicine, 349, 975–986.

    Google Scholar 

  • Carlezon, W. A., Thome, J., Olson, V. G., Lane-Ladd, S. B., Brodkin, E. S., Hiroi, N., et al. (1998). Regulation of cocaine reward by CREB. Science, 282, 2272–2275.

    Google Scholar 

  • Carvalho, R. C., Fukushiro, D. F., Helfer, D. C., Callegaro-Filho, D., Trombin, T. F., Zanlorenci, L. H., et al. (2009). Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: Role of dopamine D2 receptors. Addiction Biology, 14(3), 283–293.

    Google Scholar 

  • Center for Disease Control. (2011). Prescription painkiller overdoses in the US. Vital Signs, November 2011. Retrieved June 21, 2013 from http://www.cdc.gov/vitalsigns/painkilleroverdoses/.

  • Chklovskii, D. B., Mel, B. W., & Svoboda, K. (2004). Cortical rewiring and information storage. Nature, 431, 782–788.

    CAS  PubMed  Google Scholar 

  • Ciranna, L. (2006). Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: Implications in physiological functions and in pathology. Current Neuropharmacology, 4(2), 101–114.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Cole, R. L., Konradi, C., Douglass, J., & Hyman, S. E. (1995). Neuronal adaptation to amphetamine and dopamine: Molecular mechanisms of prodynorphin gene regulation in rat striatum. Neuron, 14, 813–823.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Dackis, C. A., & Gold, M. S. (1985). New concepts in cocaine addiction: The dopamine depletion hypothesis. Neuroscience and Biobehavioral Reviews, 9, 469–477. doi:10.1016/0149-7634(85)90022-3.

    Article  CAS  PubMed  Google Scholar 

  • Dart, R. C. (Ed.). (2004) Medical toxicology, (3rd ed.) Philadelphia: Lippincott, Williams, and Wilkins.

    Google Scholar 

  • Debonnel, G. (1993). Current hypotheses on sigma receptors and their physiological role: Possible implications in psychiatry. Journal of Psychiatry and Neuroscience, 18(4), 157–172.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Deliganis, A. V., Pierce, P. A., & Peroutka, S. J. (1991). Differential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors. Biochemical Pharmacology, 41, 1739–1744.

    CAS  PubMed  Google Scholar 

  • Drucker, G., Raikkoff, K., Neafsey, E. J., & Collins, M. A. (1990). Dopamine uptake inhibitory capacities of beta-carboline and 3,4-dihydro-beta-carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation products. Brain Research, 509(1), 125–133.

    CAS  PubMed  Google Scholar 

  • Fabregas, J. M., Gonzalez, D., Fondevila, S., Cutchet, M., Fernandez, X., & Barbosa, P. C. (2010). Assessment of addiction severity among ritual users of ayahuasca. Drug and Alcohol Dependence, 111(3), 257–326.

    PubMed  Google Scholar 

  • Fontanilla, D., Johannessen, M., Hajipour, A. R., Cozzi, N., Jackson, M. B., & Ruoho, A. E. (2009). The hallucinogen N,N-Dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science, 323(5916), 934–937.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Fuller, R. K., Branchey, L., Brightwell, D. R., Derman, R. M., Emrick, C. D., Iber, F. L., et al. (1986). Disulfiram treatment of alcoholism: A Veterans Administration cooperative study. JAMA, 256(11), 1449–1455. doi:10.1046/j.1360-0443.1998.9345157.x.

  • Gorelick, D. A. (1998). The rate hypothesis and agonist substitution approaches to cocaine abuse treatment. Advances in Pharmacology, 42, 995–997.

    CAS  PubMed  Google Scholar 

  • Grabowski, J., Rhoades, H., Silverman, P., Schmitz, J. M., Stotts, A., Creson, D., et al. (2000). Risperdone for the treatment of cocaine dependence: Randomized, double-blind trial. Journal of Clinical Psychopharmacology, 20(3), 305–310.

    CAS  PubMed  Google Scholar 

  • Grabowski, J., Shearer, J., Merrill, J., & Negus, S. S. (2004a). Agonist-like replacement pharmacotherapy for stimulant abuse and dependence. Addictive Behaviors, 29, 1439–1464.

    PubMed  Google Scholar 

  • Grabowski, J., Rhoades, H., Stotts, A., Cowan, K., Kopecky, C., Dougherty, A., et al. (2004b). Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: Two double-blind randomized clinical trials. Neuropsychopharmacology, 29(5), 969–981.

    Google Scholar 

  • Grinspoon, L., & Bakalar, J. B. (1997). Psychedelic drugs reconsidered. New York, NY: The Lindesmith Center.

    Google Scholar 

  • Grob, C. S., McKenna, D. J., Callaway, J. C., Brito, G. S., Neves, E. S., Oberlaender, G., et al. (1996). Human psychopharmacology of hoasca: A plant hallucinogen used in ritual context in Brazil. The Journal of Nervous and Mental Disease, 184(2), 86–94.

    Google Scholar 

  • Grof, S. (2008). LSD psychotherapy. Santa Cruz, CA: Multidisciplinary Association for Psychedelic Studies.

    Google Scholar 

  • Grof, S. (2009). LSD: Doorway to the numinous. Rochester, VT: Park Street.

    Google Scholar 

  • Gual, A., & Lehert, P. (2001). Acamprosate during and after acute alcohol withdrawal: A double-blind placebo-controlled study in Spain. Alcohol and Alcoholism, 36(5), 413–418. doi:10.1093/alcalc/36.5.413.

    Article  CAS  PubMed  Google Scholar 

  • Halpern, J. H., Sherwood, A. R., Passie, T., Blackwell, K. C., & Ruttenberer, A. J. (2008). Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. Medical Science Monitor, 14(8), 15–22.

    Google Scholar 

  • Henningfield, J. E. (1995). Nicotine medications for smoking cessation. New England Journal of Medicine, 333: 1196–1203.

    Google Scholar 

  • Higgins, G. A., & Fletcher, P. J. (2003). Serotonin and drug reward: Focus on 5-HT2C receptors. European Journal of Pharmacology, 480, 151–162.

    CAS  PubMed  Google Scholar 

  • Hoffer, A., & Osmond, H. (1967). The hallucinogens. New York, NY: Academic Press.

    Google Scholar 

  • Hoffman, A. (2009). LSD: My problem child. Santa Cruz, CA: Multidisciplinary Association for Psychedelic Studies.

    Google Scholar 

  • Hope, B. T., Nye, H. E., Kelz, M. B., Self, D. W., Iadarola, M. J., Nakabeppu, Y., et al. (1994). Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron, 13, 1235–1244.

    CAS  PubMed  Google Scholar 

  • Hughes, J. C., & Cook, C. C. (2006). The efficacy of disulfiram: A review of outcome studies. Addiction, 92(4), 381–395.

    Google Scholar 

  • Hyman, S. E., Malenka, R. C., & Nestler, E. J. (2006). Neural mechanisms of addiction: The role of reward-related learning and memory. Annual Review of Neuroscience, 29, 565–598.

    CAS  PubMed  Google Scholar 

  • Ichikawa, J., Ishii, H., Bonacorrso, S., Wiley, F. L., O’Laughlin, I. A., & Meltzer, H. Y. (2001). 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: A possible mechanism of atypical antipsychotic-induced cortical dopamine release. Journal of Neurochemistry, 76(5), 1521–1531.

    CAS  PubMed  Google Scholar 

  • Kalivas, P. W. (2004). Glutamate systems in cocaine addiction. Current Opinion in Pharmacology, 4(1), 23–29.

    CAS  PubMed  Google Scholar 

  • Kampman, K. M., Pettinati, H., Lynch, K. G., Sparkman, T., & O’Brien, C. P. (2003). A pilot trial of olanzapine for the treatment of cocaine dependence. Drug and Alcohol Dependence, 70(3), 265–273.

    CAS  PubMed  Google Scholar 

  • Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeison, S. J., et al. (2009). Predicting new molecular targets for known drugs. Nature: International Weekly Journal of Science, 462, 175–181.

    Google Scholar 

  • Kelley, A. E. (2004). Memory and addiction: Shared neural circuitry and molecular mechanisms. Neuron, 44, 161–179.

    CAS  PubMed  Google Scholar 

  • Kjellgren, A., Eriksson, A., & Norlander, T. (2009). Experiences of encounters with ayahuasca – “the vine of the soul”. Journal of Psychoactive Drugs, 42(4), 309–315.

    Google Scholar 

  • Koob, G. F., & Bloom, F. E. (1998). Neuroscience of addiction. Neuron, 21, 467–476.

    CAS  PubMed  Google Scholar 

  • Koob, G. F., & Le Moal, M. (1997). Drug abuse: Hedonic homeostatic dysregulation. Science, 278, 52–58.

    CAS  PubMed  Google Scholar 

  • Li, Y., Kolb, B., & Robinson, T. E. (2003). The location of persistent amphetamine-induced changes in the density of dendritic spines on medium spiny neurons in the nucleus accumbens and caudate-putamen. Neuropsychopharmacology, 28, 1082–1085.

    CAS  PubMed  Google Scholar 

  • Li, Z., Ichikawa, J., Dai, J., & Meltzer, H. Y. (2004). Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. European Journal of Psychiatry, 493(1–3), 75–83.

    CAS  Google Scholar 

  • Li, Y., Sattler, R., Yang, E. J., Nunes, A., Ayukawa, Y., Aktar. S., et al. (2011). Harmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expression. Neuropharmacology, 60(7–8), 1168–1175.

    Google Scholar 

  • Lysis. (n. d.). In Merriam-Webster’s online dictionary. Retrieved from http://www.merriam-webster.com/dictionary/lysis.

  • Mabit J. (2007). Ayahuasca in the treatment of addictions. In T. B. Robert & M. J. Winkelman (Eds.), Psychedelic medicine (vol. 2): New evidence for hallucinogenic substances as treatments (pp. 87-103). New York, NY: Praeger.

    Google Scholar 

  • Marsch, L. A. (2002). The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior, and criminality: A meta-analysis. Addiction, 93(4), 515–532. doi:10.1046/j.1360-0443.1998.9345157.x.

    Article  Google Scholar 

  • Matthews, A. M., Wilson, V. B., & Mitchell, S. H. (2011). The role of antipsychotics in smoking and smoking cessation. CNS Drugs, 25(4), 299–315.

    PubMed  Google Scholar 

  • McGregor, A., Lacosta, S., & Roberts, D. C. (1993). L-tryptophan decreases the breaking point under a progressive ratio schedule of intravenous cocaine reinforcement in the rat. Pharmacology, Biochemistry and Behavior, 44, 651–655.

    CAS  PubMed  Google Scholar 

  • McKenna, D. J., Towers, G. H. N., & Abbott, F. (1984). Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and B-carboline constituents of ayahuasca. Journal of Ethnopharmacology, 10, 195–223.

    CAS  PubMed  Google Scholar 

  • Metzner, R. (1999). Sacred vine of spirits: Ayahuasca. Rochester, VT: Park Street Press.

    Google Scholar 

  • Millan, M.J., Dekeyne, A., & Gobert, A. (1998). Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology, 37(7), 935–955.

    Google Scholar 

  • Molliver, M. E. (1987). Serotonergic neuronal systems: What their anatomic organization tells us about function. Journal of Clinical Psychopharmacology, 7(Suppl 6), 3S–23S.

    CAS  PubMed  Google Scholar 

  • Moore, R. Y., & Bloom, F. E. (1978). Central catecholamine neuron systems: Anatomy and physiology of the dopamine systems. Annual Review of Neurosciences, 1, 129–169.

    CAS  Google Scholar 

  • Morton, W. A. (1999). Cocaine and psychiatric symptoms. Primary Care Companion to the Journal of Clinical Psychiatry, 1(4), 109–113.

    PubMed  PubMed Central  Google Scholar 

  • Navarro, G., Moreno, E., Bonaventura, J., Brugarolas, M., Farré, D., Aguinaga, D., et al. (2013). Cocaine inhibits dopamine D2 receptor signaling via sigma-1-D2 receptor heteromers. PLoS One, 8(4), e61245.

    Google Scholar 

  • Negus, S. S., & Mello, N. K. (2003a). Effects of chronic d-amphetamine treatment on cocaine and food-maintained responding under a second-order schedule in Rhesus monkeys. Drug and Alcohol Dependence, 70, 39–52.

    Google Scholar 

  • Negus, S. S., & Mello, N. K. (2003b). Effects of chronic d-amphetamine treatment on cocaine and food-maintained responding under a progressive-ratio schedule in Rhesus monkeys. Psychopharmacology, 167, 324–332.

    Google Scholar 

  • Osorio, F. L., Macedo, L. R., Sousa, J. P., Pinto, J. P., Quevedo, J., Crippa, J. A., et al. (2011). The therapeutic potential of harmine and ayahuasca in depression: Evidence from exploratory animal and human studies. In R. G. dos Santos (Ed.), The ethnopharmacology of ayahuasca (pp. 75–78). Kerala, India: Transworld Research Network. Retrieved June 21, 2013 from http://issuu.com/researchsignpost/docs/rafael.

  • Overman, G. P., Teter, C. J., & Guthrie, S. K. (2003). Acamprosate for the adjunctive treatment of alcohol dependence. Annals of Pharmacotherapy, 37(7), 1090–1099. doi:10.1345/aph.1C351.

    Article  CAS  Google Scholar 

  • Pahnke, W. N., Kurland, A. A., Unger, S., Savage, C., & Grof, S. (1970). The experimental use of psychedelic psychotherapy. JAMA, 212(11), 1856–1863.

    CAS  PubMed  Google Scholar 

  • Pierce, R. C., & Kumaresan, V. (2006). The mesolimbic dopamine system: The final common pathway for the reinforcing effect of DOA? Neuroscience and Biobehavioral Reviews, 30(2), 215–238.

    CAS  PubMed  Google Scholar 

  • Psyche. (n. d.). In Merriam-Webster’s online dictionary. Retrieved from http://www.merriam-webster.com/dictionary/psyche.

  • Purves, D., Augustine, G. J., Fitzpatrick, D., & Hall, W. C. (Eds.). (2011). Neuroscience. Sunderland, CT: Sinauer.

    Google Scholar 

  • Robinson, T. E., & Kolb, B. (1999). Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and pre-frontal cortex following repeated treatment with amphetamine or cocaine. European Journal of Neuroscience, 11, 1598–1604.

    CAS  Google Scholar 

  • Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J. Hurst, R. S., Lebel, L. A., et al. (2007). Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology, 52(3), 985–994.

    Google Scholar 

  • Rothman, R. B., & Baumann, M. H. (2003). Monoamine transporters and psychostimulant drugs. European Journal of Pharmacology, 479, 23–40.

    CAS  PubMed  Google Scholar 

  • Rothman, R. B., & Baumann, M. H. (2006). Balance between dopamine and serotonin release modulates behavior effects of amphetamine-type drugs. Annals of the New York Academy of Sciences, 1074, 245–260.

    CAS  PubMed  Google Scholar 

  • Rothman, R. B., Blough, B. E., Woolverton, W. L., Anderson, K. G., Negus, S. S., Mello, N. K., et al. (2005). Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. Journal of Pharmacology and Experimental Therapeutics, 313, 1361–1369.

    Google Scholar 

  • Rothman, R. B., Blough, B. E., & Baumann, M. H. (2006). Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. AAPS Journal, 9(1), E1–E10. doi:10.1208/aapsj0901001.

    Article  Google Scholar 

  • Rothman, R. B., Blough, B. E., & Baumann, M. H. (2008). Dual dopamine/serotonin releasers: Potential treatment agents for stimulant addiction. Experimental and Clinical Psychopharmacology, 16(6), 458–474.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ruck, C. A., Bigwood, J., Staples, D., Ott, J., & Wasson, R. G. (1979). Entheogens. Journal of Psychedelic Drugs, 11, 145–146.

    CAS  PubMed  Google Scholar 

  • Substance Abuse Mental Health Services Administration. (2012). Results from the 2010 National Survey on Drug Use and Health: Summary of national findings. U.S. Department of Health and Human Services. Retrieved from http://www.samhsa.gov/data/NSDUH/2k10ResultsTables/NSDUHTables2010R/HTM/Sect1peTabs1to46.htm#Tab1.1A.

  • Schultes, R. E., Hofmann, A., & Ratsch, C. (1998). Plants of the gods: Their sacred, healing, and hallucinogenic powers. Rochester, VT: Healing Arts Press.

    Google Scholar 

  • Shanon, B. Moments of insight, healing, and transformation: A cognitive phenomenological analysis. In this volume.

    Google Scholar 

  • Shanon, B. (2002). The antipodes of the mind: Charting the phenomenology of the ayahuasca experience. Oxford: Oxford University Press.

    Google Scholar 

  • Shulgin, Al, & Shulgin, An. (1997). Tihkal: The continuation. Berkeley, CA: Transform.

    Google Scholar 

  • Smith, C. (1958). A new adjunct to the treatment of alcoholism: The hallucinogenic drugs. Quarterly Journal for the Studies of Alcohol, 19, 406–417.

    Google Scholar 

  • Smith, F. L., Yu, D. S., Smith, D. G., Leccese, A. P., & Lyness, W. H. (1986). Dietary tryptophan supplements attenuate amphetamine self-administration in the rat. Pharmacology, Biochemistry, and Behavior, 25(4), 849–855.

    CAS  PubMed  Google Scholar 

  • Smith, R. L., Canton, H., Barrett, R. J., & Sanders-Bush, E. (1998). Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors. Pharmacology, Biochemistry, and Behavior, 61(3), 323–330.

    CAS  PubMed  Google Scholar 

  • Spanagel, R., Herz, A., & Shippenberg, T. S. (1992). Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proceedings of the National Academy of Sciences, 89, 2046–2050.

    CAS  Google Scholar 

  • Stace, W. T. (1961). Mysticism and philosophy. London: Macmillan.

    Google Scholar 

  • Stahl, S. M. (2008). Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications. New York, NY: Cambridge University Press.

    Google Scholar 

  • Steinbusch, H. W. (1981). Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals. Neuroscience, 6, 557–618.

    CAS  PubMed  Google Scholar 

  • Steiner, H., & Gerfen, C. R. (1996). Dynorphin regulates D1 dopamine receptor-mediated responses in the striatum: Relative contributions of pre- and postsynaptic mechanisms in dorsal and ventral striatum demonstrated by altered immediate-early gene induction. Journal of Comparative Neurology, 376, 530–541.

    CAS  Google Scholar 

  • Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H., & Robert, K. (1994). Dose response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Archives of General Psychiatry, 51(2), 98–108.

    CAS  PubMed  Google Scholar 

  • Strassman, R. (2001). DMT: The spirit molecule. Rochester, VT: Park Street.

    Google Scholar 

  • Thomas, M. J., Kalivas, P. W., & Shaham, Y. (2009). Neuroplasticity in the mesolimbic dopamine system and cocaine addiction. British Journal of Pharmacology, 154(2), 327–342.

    Google Scholar 

  • Trichter, S., Klimo, J., & Krippner, S. (2009). Changes in spirituality among ayahuasca ceremony novice participants. Journal of Psychoactive Drugs, 41(2), 121–134.

    PubMed  Google Scholar 

  • Ungerstedt, U. (1971). Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiologica Scandinavica Supplement, 367, 1–48.

    CAS  Google Scholar 

  • United Nations Office of Drugs and Crime. (2012). World drug report. New York, NY: United Nations. Retrieved June 21, 2013 from http://www.unodc.org/documents/data-and-analysis/WDR2012/WDR_2012_web_small.pdf.

  • W. W. (1994). The society of Alcoholics Anonymous (reprinted). American Journal of Psychiatry, 151(6), 259–262.

    Google Scholar 

  • Wise, R. A. (1980). The dopamine synapse and the notion of “pleasure centers” in the brain. Trends in Neurosciences, 3, 91–95.

    CAS  Google Scholar 

  • Wojnicki, F. H. E., Rothman, R. B., Rice, K. C., Glowa, J. R. (1999). Effects of phentermine on responding maintained under multiple fixed-ratio schedules of food and cocaine presentation in the Rhesus monkey. Journal of Pharmacology and Experimental Therapeutics, 288, 550–560.

    Google Scholar 

  • Yokell, M. A., Zaller, N. D., Green, T. C., & Rich, J. D. (2011). Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: An international review. Current Drug Abuse Reviews, 4(1), 28–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang, D., Zhang, L., Tang, Y., Zhang, Q., Lou, S., Sharp, F. R., et al. (2005). Repeated cocaine administration induces gene expression changes through the dopamine D1 receptors. Neuropsychopharmacology, 30, 1443–1454.

    Google Scholar 

  • Zhihua, X., & Miller, G. M. (2007). Trace amine-associated receptor 1 is a modulator of the dopamine transporter. The Journal of Pharmacology and Experimental Therapeutics, 321, 128–136.

    Google Scholar 

  • Zinberg, N. E. (1984). Drug, set, and setting: The basis for controlled intoxicant use. New Haven, CT: Yale University Press.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, The University of Arizona, Tucson, AZ, USA

    James I. Prickett

  2. PO Box 302, Monument, CO, 80132, USA

    Mitchell B. Liester

Authors
  1. James I. Prickett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitchell B. Liester
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mitchell B. Liester .

Editor information

Editors and Affiliations

  1. Center for Economic Research and Education (CIDE), Aguascalientes, AGS, Mexico

    Beatriz Caiuby Labate

  2. Nucleus for Interdisciplinary Studies of Psychoactives (NEIP), San Francisco, CA, USA

    Clancy Cavnar

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Prickett, J.I., Liester, M.B. (2014). Hypotheses Regarding Ayahuasca’s Potential Mechanisms of Action in the Treatment of Addiction. In: Labate, B.C., Cavnar, C. (eds) The Therapeutic Use of Ayahuasca. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-40426-9_7

Download citation

Publish with us

Policies and ethics

Search

Navigation